Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus MPI KRYPTON 81M GENERATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus MPI KRYPTON 81M GENERATOR.
FLUDEOXYGLUCOSE F18 vs MPI KRYPTON 81M GENERATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
Krypton-81m (81mKr) is a short-lived radionuclide that decays by isomeric transition emitting gamma rays (190 keV). When inhaled, it distributes in the lungs according to regional ventilation. Imaging is performed using a gamma camera to assess pulmonary ventilation. The generator produces 81mKr from its parent rubidium-81 (81Rb).
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
Intravenous infusion of krypton-81m gas in oxygen, typically 400-800 MBq (10-20 mCi) per study, administered via generator elution with a flow rate of 500-1000 mL/min. Adult dose per lung ventilation study: 100-400 MBq (2.7-10.8 mCi) inhaled in a single breath or continuous breathing for 1-2 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Physical half-life of krypton-81m: 13.1 seconds; biological half-life is negligible as it is inert gas eliminated via exhalation.
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Renal: ~100% (krypton-81m is exhaled and decay products are excreted renally; as a gas, the primary elimination is via exhalation, with the decay product rubidium-81 cleared renally).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical